Tumor Immunogenicity

Tumor immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. Immunogenicity, which is the ability to induce adaptive immune responses, has been widely analysed by cancer cell transplantation experiments. If rejection requires prior immunization, those transplanted cancer cells (which are known as progressors) are considered intermediate immunogenic. Failure to reject the tumour following immunization against trans-planted cancer cells classifies them as non-immunogenic.

  • Immune adaptations
  • Innate immunity Development
  • Benign Tumors
  • Malignant Tumors
  • Differentiation of Tumors

Related Conference of Tumor Immunogenicity

June 29-July 01, 2017

8th European Immunology Conference

Madrid, Spain
July 03-05, 2017

9th Asia-Pacific Global Summit on Healthcare & Immunology

Kuala Lumpur, Malaysia
July 12-13, 2017

3rd World Conference on Parasitology & Pathogenesis

Chicago, Illinois, USA
September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 11-12, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
April 16-17, 2018

EuroSciCon Conference on StemCell

Amsterdam, Netherlands
July 05-07, 2018

EuroSciCon Conference on Immunology

Vienna, Austria

Tumor Immunogenicity Conference Speakers

Recommended Sessions

Related Journals

Are you interested in